WO2021118199A3 - P53을 활성화하는 펩타이드를 포함하는 조성물 - Google Patents

P53을 활성화하는 펩타이드를 포함하는 조성물 Download PDF

Info

Publication number
WO2021118199A3
WO2021118199A3 PCT/KR2020/017836 KR2020017836W WO2021118199A3 WO 2021118199 A3 WO2021118199 A3 WO 2021118199A3 KR 2020017836 W KR2020017836 W KR 2020017836W WO 2021118199 A3 WO2021118199 A3 WO 2021118199A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
peptide
seborrhea
alleviation
interaction
Prior art date
Application number
PCT/KR2020/017836
Other languages
English (en)
French (fr)
Other versions
WO2021118199A2 (ko
Inventor
한장희
김민서
Original Assignee
강원대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강원대학교산학협력단 filed Critical 강원대학교산학협력단
Priority to JP2022534627A priority Critical patent/JP2023505796A/ja
Priority to EP20898358.5A priority patent/EP4074303A4/en
Priority to US17/757,020 priority patent/US20230021365A1/en
Publication of WO2021118199A2 publication Critical patent/WO2021118199A2/ko
Publication of WO2021118199A3 publication Critical patent/WO2021118199A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Abstract

본 발명은 특정 펩타이드를 유효성분으로 포함하는 피지 과다분비의 억제 또는 개선용 화장료 조성물 및 피지 과다분비의 예방, 개선 또는 치료용 약학 조성물을 제공한다. 상기 펩타이드는 p53과 MDM2의 상호작용을 현저하게 감소시키고. 그 결과 p53과 RNA 폴리머라아제 II(RNA Polymerase II, POLII)의 상호작용을 현저하게 증가시킴으로써, 피지세포의 사멸(apoptosis)을 유도하는 사이토카인의 발현을 유도할 수 있다.
PCT/KR2020/017836 2019-12-10 2020-12-09 P53을 활성화하는 펩타이드를 포함하는 조성물 WO2021118199A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022534627A JP2023505796A (ja) 2019-12-10 2020-12-09 Ｐ５３活性化ペプチドを含む組成物
EP20898358.5A EP4074303A4 (en) 2019-12-10 2020-12-09 COMPOSITION COMPRISING A P53 ACTIVATING PEPTIDE
US17/757,020 US20230021365A1 (en) 2019-12-10 2020-12-09 Composition comprising p53-activating peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0163920 2019-12-10
KR1020190163920A KR102268921B1 (ko) 2019-12-10 2019-12-10 p53을 활성화하는 펩타이드를 포함하는 조성물

Publications (2)

Publication Number Publication Date
WO2021118199A2 WO2021118199A2 (ko) 2021-06-17
WO2021118199A3 true WO2021118199A3 (ko) 2021-07-29

Family

ID=76328942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/017836 WO2021118199A2 (ko) 2019-12-10 2020-12-09 P53을 활성화하는 펩타이드를 포함하는 조성물

Country Status (5)

Country Link
US (1) US20230021365A1 (ko)
EP (1) EP4074303A4 (ko)
JP (1) JP2023505796A (ko)
KR (1) KR102268921B1 (ko)
WO (1) WO2021118199A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681701B1 (ko) * 2005-12-30 2007-02-15 주식회사 코리아나화장품 헥사노일트리펩타이드를 유효성분으로 함유하는 여드름완화용 화장료 조성물
KR100722675B1 (ko) * 2005-12-27 2007-05-29 주식회사 코리아나화장품 글루콘산 및 헥사노일트리펩타이드를 유효성분으로함유하는 피부 각질 제거용 화장료 조성물
KR20110128926A (ko) * 2009-03-16 2011-11-30 디에스엠 아이피 어셋츠 비.브이. 트리펩타이드의 용도
KR20180099092A (ko) * 2017-02-28 2018-09-05 강원대학교산학협력단 β1 인테그린 신호전달 억제 활성을 갖는 펩타이드 및 이를 포함하는 약학 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101061017B1 (ko) * 2009-10-23 2011-08-31 (주) 수파드엘릭사 암세포의 성장 및/또는 전이 억제용 약학 조성물
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
KR20180012833A (ko) * 2015-05-29 2018-02-06 창이즈 태그히비글로우 피지의 과잉 생산과 연관된 피부 상태를 치료하기 위한 폴리펩티드 및 항체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100722675B1 (ko) * 2005-12-27 2007-05-29 주식회사 코리아나화장품 글루콘산 및 헥사노일트리펩타이드를 유효성분으로함유하는 피부 각질 제거용 화장료 조성물
KR100681701B1 (ko) * 2005-12-30 2007-02-15 주식회사 코리아나화장품 헥사노일트리펩타이드를 유효성분으로 함유하는 여드름완화용 화장료 조성물
KR20110128926A (ko) * 2009-03-16 2011-11-30 디에스엠 아이피 어셋츠 비.브이. 트리펩타이드의 용도
KR20180099092A (ko) * 2017-02-28 2018-09-05 강원대학교산학협력단 β1 인테그린 신호전달 억제 활성을 갖는 펩타이드 및 이를 포함하는 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELVADOREEN: "Hans Peptide No Sebum Sebum Management Cream Brightening [Ultimate Relief Cream]", 22 July 2018 (2018-07-22), pages 1 - 14, XP055830859, Retrieved from the Internet <URL:https://m.blog.naver.com/girlhat/221324296609> *

Also Published As

Publication number Publication date
EP4074303A2 (en) 2022-10-19
JP2023505796A (ja) 2023-02-13
WO2021118199A2 (ko) 2021-06-17
KR102268921B1 (ko) 2021-06-23
US20230021365A1 (en) 2023-01-26
KR20210073275A (ko) 2021-06-18
EP4074303A4 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
WO2020160193A3 (en) Compounds and uses thereof
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
WO2020198403A3 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
EP3757105A3 (en) Polycyclic pyridone derivative having integrase inhibitory activity
WO2016142708A3 (en) Pharmaceutical composition
EP3819298A4 (en) COMPOSITION WITH TRKA INHIBITIVE EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR RELIEF OF PAIN THEREOF AS AN ACTIVE SUBSTANCE
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
EP3760626A4 (en) NEW COMPOUND AND COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS, INCLUDING IT AS AN ACTIVE SUBSTANCE
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
EP3964520A4 (en) NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
WO2020068950A8 (en) Hdac1,2 inhibitors
WO2021118199A3 (ko) P53을 활성화하는 펩타이드를 포함하는 조성물
EP4023234A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER, CONTAINING A POLYPHENOL COMPOUND USED AS ACTIVE PRINCIPLE
EP3895719A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SAKEI WIKIM30 AS AN ACTIVE SUBSTANCE TO PREVENT OR TREAT CANCER
WO2020122838A3 (en) A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
MX2021006138A (es) Otros compuestos heteroaromaticos que tienen actividad contra el vrs.
WO2019098572A3 (ko) 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
WO2022032073A3 (en) Trpml modulators
WO2020139237A3 (en) A bilayer tablet formulation of atorvastatin calcium and ezetimibe
WO2020159159A3 (ko) 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20898358

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022534627

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020898358

Country of ref document: EP

Effective date: 20220711